Axonics Inc (AXNX) Stock Price, Quote, News and Overview
NASDAQ:AXNX - Nasdaq - US05465P1012 - Common Stock - Currency: USD
AXNX Quote, Performance and Key Statistics
70.98
+0.53 (+0.75%)
The current stock price of AXNX is 70.98 USD. In the past month the price increased by 0.97%. In the past year, price increased by 26.1%.
AXNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About AXNX
Company Profile
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The company went IPO on 2018-10-31. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Company Info
Axonics Inc
26 Technology Drive
Irvine CALIFORNIA 92618 US
CEO: Raymond W. Cohen
Employees: 797
Company Website: https://www.axonics.com/
Phone: 19493966322
Axonics Inc / AXNX FAQ
What is the stock price of Axonics Inc today?
The current stock price of AXNX is 70.98 USD. The price increased by 0.75% in the last trading session.
What is the ticker symbol for Axonics Inc stock?
The exchange symbol of Axonics Inc is AXNX and it is listed on the Nasdaq exchange.
On which exchange is AXNX stock listed?
AXNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Axonics Inc stock?
19 analysts have analysed AXNX and the average price target is 73.33 USD. This implies a price increase of 3.31% is expected in the next year compared to the current price of 70.98. Check the Axonics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Axonics Inc worth?
Axonics Inc (AXNX) has a market capitalization of 3.63B USD. This makes AXNX a Mid Cap stock.
How many employees does Axonics Inc have?
Axonics Inc (AXNX) currently has 797 employees.
What are the support and resistance levels for Axonics Inc (AXNX) stock?
Axonics Inc (AXNX) has a support level at 70.48 and a resistance level at 70.99. Check the full technical report for a detailed analysis of AXNX support and resistance levels.
Is Axonics Inc (AXNX) expected to grow?
The Revenue of Axonics Inc (AXNX) is expected to grow by 23.72% in the next year. Check the estimates tab for more information on the AXNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Axonics Inc (AXNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AXNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AXNX, evaluating the profitability, health, valuation and growth aspects
- Axonics Inc (AXNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Axonics Inc (AXNX) Sales and EPS estimates to see what analysts future expectations are.
- Axonics Inc (AXNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Axonics Inc (AXNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Axonics Inc (AXNX) Stock Chart to make your own analysis
- Axonics Inc (AXNX) Latest news and press-releases to stay up to date.
Does Axonics Inc (AXNX) stock pay dividends?
AXNX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Axonics Inc (AXNX)?
Axonics Inc (AXNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.01).
AXNX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AXNX. When comparing the yearly performance of all stocks, AXNX turns out to be only a medium performer in the overall market: it outperformed 65.53% of all stocks.
AXNX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AXNX. No worries on liquidiy or solvency for AXNX as it has an excellent financial health rating, but there are worries on the profitability.
AXNX Financial Highlights
Over the last trailing twelve months AXNX reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -116.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| Debt/Equity | 0 |
AXNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 68% to AXNX. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 56.54% and a revenue growth 23.72% for AXNX